Christine Mummery - Galapagos Non-Executive Independent Director
| GLPG Stock | USD 29.07 0.01 0.03% |
Director
Dr. Christine Mummery was appointed as NonExecutive Independent Director effective as of Galapagos NV since November 4, 2015. As of 2008, Dr. Christine Mummery is Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at the Leiden University Medical Centre in The Netherlands. After her PhD in BioPhysics at London University, she was postdoctoral fellow at the Hubrecht Institute in Utrecht, later also staff member and group leader. She became Professor at the Interuniversity Cardiology of the Netherlands at the University Medical Centre Utrecht in 2002. In 2007, she was a joint Harvard Stem Cell InstituteRadcliffe fellow at Harvard and Massachusetts General Hospital at the time human induced pluripotent stem cells were being developed and was the first to derive iPSC lines from patients. Her primary research focus is currently the development and use of stem cells in cardiovascular development and disease. She served on the Ethical Councils of the Ministry of Health, is member of the Royal Netherlands Academy of Arts and Sciences, editor in chiefeditorial board member of several journals, former board member of ISSCR and pastpresident of the International Society of Differentiation. In addition, she is on the board of ZonMW and chairs the executive board of the hDMT Institute for human Organ and Disease Model technologies, a nonprofit RD institute of which Galapagos is a founding partner. since 2015.
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 |
| Phone | 32 1 534 29 00 |
| Web | https://www.glpg.com |
Galapagos Management Efficiency
The company has return on total asset (ROA) of (0.0111) % which means that it has lost $0.0111 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Galapagos' Return On Equity is most likely to increase slightly in the upcoming years. At this time, Galapagos' Total Current Assets are most likely to increase significantly in the upcoming years. The Galapagos' current Intangible Assets is estimated to increase to about 134.3 M, while Intangibles To Total Assets are projected to decrease to 0.04.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Southwell | Spero Therapeutics | 56 | |
| Frank Thomas | Spero Therapeutics | 47 | |
| JeanFranois Formela | Spero Therapeutics | 61 | |
| Elaine Jones | CytomX Therapeutics | 60 | |
| Patricia Tilton | Instil Bio | N/A | |
| Paul Newfield | Instil Bio | N/A | |
| Neil Exter | CytomX Therapeutics | 57 | |
| Patrick Vink | Spero Therapeutics | 54 | |
| Roger Loeb | Instil Bio | N/A | |
| Frederick Gluck | CytomX Therapeutics | 82 | |
| William Lupien | Instil Bio | 73 | |
| George Rohlinger | Instil Bio | N/A | |
| Gaurav Swarup | Instil Bio | 60 | |
| Anthony Altig | Assembly Biosciences | 61 | |
| John Scarlett | CytomX Therapeutics | 67 | |
| Timothy Shannon | CytomX Therapeutics | 56 | |
| Fiona Oliver | Instil Bio | N/A | |
| Matthew Young | CytomX Therapeutics | 49 | |
| Charles Fuchs | CytomX Therapeutics | 57 | |
| James Meyers | CytomX Therapeutics | 54 | |
| Veena Hingarh | Instil Bio | N/A | |
Management Performance
| Return On Equity | -0.0015 | ||||
| Return On Asset | -0.0111 |
Galapagos NV ADR Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rajesh Parekh, Non-Executive Chairman of the Board | ||
| John Montana, Managing Argenta | ||
| Marieke Vermeersch, Head Communication | ||
| Ellen Aar, Head Development | ||
| Annelies Missotten, Executive Officer | ||
| Michele MBA, Head Commercial | ||
| Piet Wigerinck, Chief Scientific Officer | ||
| Chantal Tasset, Head Devel | ||
| Sofie Gijsel, Head Relations | ||
| Valeria Cnossen, Executive Counsel | ||
| Christine Mummery, Non-Executive Independent Director | ||
| Bart Filius, CFO | ||
| Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director | ||
| PharmD Raboisson, Head VP | ||
| Andre Hoekema, Sr. VP of Corporate Devel. | ||
| Katrine Bosley, Independent Non-Executive Director | ||
| Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | ||
| Howard Rowe, Non-Executive Independent Director | ||
| Dirk Naeyer, Head Operations | ||
| Alice Dietrich, Head Affairs | ||
| Harrold Barlingen, Non-Executive Director | ||
| Philippe Alen, Senior Development | ||
| Elizabeth Goodwin, VP Corporate Communications & Investor Relations | ||
| Mary Kerr, Non-Executive Independent Director | ||
| Thad Huston, CFO COO | ||
| MBA MBA, COO Pres | ||
| Werner Cautreels, Non-Executive Independent Director |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0015 | ||||
| Return On Asset | -0.0111 | ||||
| Profit Margin | 0.88 % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | (1.76 B) | ||||
| Shares Outstanding | 65.9 M | ||||
| Shares Owned By Institutions | 30.58 % | ||||
| Number Of Shares Shorted | 1.42 M | ||||
| Price To Earning | (15.60) X | ||||
| Price To Book | 0.66 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Galapagos in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Galapagos' short interest history, or implied volatility extrapolated from Galapagos options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Galapagos Stock analysis
When running Galapagos' price analysis, check to measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Galapagos' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galapagos. If investors know Galapagos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galapagos listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.19 | Earnings Share (0.06) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.12) | Return On Assets (0.01) |
The market value of Galapagos NV ADR is measured differently than its book value, which is the value of Galapagos that is recorded on the company's balance sheet. Investors also form their own opinion of Galapagos' value that differs from its market value or its book value, called intrinsic value, which is Galapagos' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galapagos' market value can be influenced by many factors that don't directly affect Galapagos' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.